According to Seelos Therapeutics, the Japanese Patent Office has issued Japanese patent number 6722453, titled “Anxiolytic Composition, Formulation and Method of Use,” covering the company’s SLS-002 intranasal racemic ketamine formulation for treatment of anxiety due to phobias. In addition, the company said that it received a notice of allowance for Japanese patent application number 2018-124196 covering SLS-002 for anxiety in patients preparing to undergo medical or dental procedures.
SLS-002 has Fast Track designation in the US for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder, and earlier this year, the company said that it had scheduled a Type C meeting with the FDA regarding a Phase 3 trial of the nasal spray for that indication.
Read the Seelos Therapeutics press release.
